NEW YORK, Feb 14 (Reuters) - A federal judge ruled that a doctor and a lawyer must return confidential marketing materials to Eli Lilly & Co. regarding anti-psychotic drug Zyprexa and said they had ...

$800 million is a ton of money to settle a civil suit, but two Houston attorneys helped win a settlement of that size this morning. Joel Androphy, who specializes in whistleblower suits, worked with ...

INDIANAPOLIS -- Eli Lilly & Co. taught its sales force a catchy slogan to peddle the antipsychotic drug Zyprexa for treating the elderly. Company salespeople told care providers that 5 milligrams of ...

Eli Lilly's bestselling drug, Zyprexa, has been on the market since 1996 and grosses $4.3 billion a year. Doctors have found it an effective treatment for schizophrenia, but it's becoming increasingly ...

South Carolina's attorney general said Friday that the state has reached a $45 million settlement with drug-maker Eli Lilly & Co. over the company's marketing of an anti-psychotic drug, an agreement ...

A personal injury lawsuit was filed seeking damages against Eli Lilly And Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Kaiser Permanente, alleging their antipsychotic medications Risperdal and ...

The Second Circuit has reversed Eastern District Judge Jack B. Weinstein's 2008 decision to certify a class of third-party payers who claimed Eli Lilly and Company's misrepresentations about Zyprexa ...

NEW YORK (Reuters) - The state of Connecticut sued Eli Lilly and Co on Tuesday, accusing the drugmaker of illegally marketing and concealing serious side effects of its top-selling schizophrenia ...

INDIANAPOLIS -- Eli Lilly and Co. has won federal approval to sell an injectable version of its top-selling anti-psychotic Zyprexa, giving doctors a new option to quickly calm agitated patients. The ...

NEW YORK (MarketWatch) -- Eli Lilly and Co. said Tuesday that it is in advanced talks to resolve ongoing probes by the U.S. Attorney's Office for the Eastern District of Pennsylvania related to past U ...

INDIANAPOLIS – Eli Lilly & Co’s. quarterly profit dropped 27 percent after its top-selling Zyprexa schizophrenia treatment lost U.S. patent protection and saw competition from generic rivals. The ...

Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro hardly ...